Technology - Prosemble

The Science

At the core of Prosemble’s technology is a patented protein-based nanoparticle (PNP) system, distinct from existing drug carriers like albumin or ferritin.

These nanoparticles remain monomeric until they polymerise in response to ATP and subsequently depolymerise under ATP hydrolysis or low pH conditions, ensuring targeted drug release. The atomic structure has been determined through cryo-electron microscopy, enabling precise engineering for disease-specific targeting. This system successfully integrates various therapeutic payloads, including Doxorubicin and small proteins, offering a scalable and adaptable solution for oncology treatments.

Key Features

Protein-Based Nanoparticle System

Designed for controlled drug delivery, polymerising in response to ATP and breaking down under tumour-specific conditions.
ATP-Responsive & pH-Triggered Release

Ensures precise drug activation within the tumour microenvironment, minimising systemic toxicity.
Versatile Cargo Loading

Capable of encapsulating a wide range of therapeutics, from chemotherapy agents like Doxorubicin to small proteins.
Atomic-Level Precision

Cryo-EM structure determination enables fine-tuned engineering for targeted therapy, maximising treatment efficiency.
Cost-Effective Alternative to ADCs

Unlike antibody-drug conjugates (ADCs), our technology offers a significantly lower manufacturing cost, making it more accessible and scalable.

Our Proteinaceous Nanoparticle (PNP) Technology

Our proteinaceous nanoparticle (PNP) technology is conceptually aligned with targeted therapeutic strategies such as antibody–drug conjugates (ADCs), which employ antibody-mediated delivery of cytotoxic agents. However, unlike ADCs, our system enables receptor-targeting peptides to be genetically encoded directly into the amino acid sequence. This confers a high degree of modularity, allowing for straightforward adaptation to different receptors via ATP-triggered assembly.

Drug incorporation within our platform occurs through passive encapsulation rather than covalent conjugation, thereby permitting the simultaneous inclusion of multiple therapeutic agents within a single nanoparticle formulation. This feature supports the delivery of optimised drug combinations, tailored to achieve enhanced efficacy and reduced toxicity across specific pathological contexts.

ADCs necessitate the complex and time-intensive production of fully matured antibodies in mammalian cell culture, followed by chemical conjugation of the payload—processes that contribute to substantial treatment costs (typically in the region of £1,000s per dose). In contrast, our PNP system is cost-effective to manufacture, readily scalable, and does not depend on intricate bioprocessing workflows.

AI & Data Science

Prosemble’s AI-driven drug formulation platform enhances precision medicine by predicting optimal nanoparticle formulations, drug interactions, and release profiles.

Our proprietary AI model analyses vast datasets to refine encapsulation methods, ensuring optimal drug stability and efficacy. By addressing multi-drug interactions and optimising dosing strategies, our technology accelerates development, reduces trial-and-error, and streamlines regulatory approvals. This data-driven innovation helps pharmaceutical partners bring safer, more effective therapies to market faster, transforming cancer care through advanced AI integration. Combining proprietary AI models with cutting-edge neural networks, we bridge chemistry and medicine through a holistic, multi-endpoint approach.

Trained on curated datasets, our models uncover novel encapsulation methods and synergistic drug combinations that enhance safety and efficacy. By leveraging structural biology, cheminformatics, and high-quality data, we deliver robust, reliable results, giving partners a distinct edge in therapeutic development.